IndustryCompany release

Gedeon Richter lifts 2026 guidance after nine-month constant-currency pharma growth of 11.7%

Gedeon Richter · Tue 10 Nov 2026

The Hungarian drugmaker reports reported pharma revenue up 2.6% to HUF 686.5bn despite a roughly 9-point currency drag, and raises its full-year outlook.

Gedeon Richter published its results for the first three quarters of 2026 on 10 November 2026. Reported pharmaceutical revenues rose 2.6% to HUF 686.5bn, while constant-currency pharma revenue growth was 11.7%. The company put the currency drag at roughly nine percentage points.

Net profit rose 7% to HUF 174.9bn over the period.

The company attributed growth to three areas: cariprazine, marketed as Vraylar and Reagila; biosimilars and contract development and manufacturing (CDMO); and Women's Healthcare, including Ryeqo and Lenzetto.

On the back of the nine-month performance, Richter raised its full-year 2026 guidance. It now expects constant-currency revenue growth of more than 10% and Clean EBIT growth in the high teens. The summary available does not give the previous guidance range or any segment-level figures.

What it means for your team

  • Currency effects, not demand, explain most of the gap between reported (2.6%) and constant-currency (11.7%) pharma growth, so teams benchmarking against Richter should note which basis is used.
  • Cariprazine, biosimilars/CDMO and women's health products are the stated growth drivers, relevant for partners, competitors and payers in those categories.
  • The raised guidance signals confidence in the full-year outlook, but the source summary gives no detail on pricing, reimbursement or regulatory developments behind it.

Company's press release: Gedeon Richter ↗

Article written by VigiEye from the official source (Gedeon Richter). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →